KR102741437B1 - Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 - Google Patents
Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 Download PDFInfo
- Publication number
- KR102741437B1 KR102741437B1 KR1020207029906A KR20207029906A KR102741437B1 KR 102741437 B1 KR102741437 B1 KR 102741437B1 KR 1020207029906 A KR1020207029906 A KR 1020207029906A KR 20207029906 A KR20207029906 A KR 20207029906A KR 102741437 B1 KR102741437 B1 KR 102741437B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- methyl
- carboxamide
- pyridin
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646432P | 2018-03-22 | 2018-03-22 | |
| US62/646,432 | 2018-03-22 | ||
| PCT/US2019/023111 WO2019183186A1 (en) | 2018-03-22 | 2019-03-20 | Heterocyclic compounds comprising pyridine useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200135425A KR20200135425A (ko) | 2020-12-02 |
| KR102741437B1 true KR102741437B1 (ko) | 2024-12-10 |
Family
ID=66001366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207029906A Active KR102741437B1 (ko) | 2018-03-22 | 2019-03-20 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 피리딘을 포함하는 헤테로시클릭 화합물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11597721B2 (enExample) |
| EP (1) | EP3768667B1 (enExample) |
| JP (1) | JP7485609B2 (enExample) |
| KR (1) | KR102741437B1 (enExample) |
| CN (1) | CN111936486B (enExample) |
| ES (1) | ES2944733T3 (enExample) |
| WO (1) | WO2019183186A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| ES2981764T3 (es) * | 2020-03-11 | 2024-10-10 | Beijing Innocare Pharma Tech Co Ltd | Compuestos heterocíclicos para inhibir las actividades de TYK2 |
| US20230295119A1 (en) | 2020-04-14 | 2023-09-21 | Gossamer Bio Services, Inc. | Substituted pyridines for the treatment of inflammatory diseases |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CN115141149A (zh) * | 2021-03-30 | 2022-10-04 | 浙江文达医药科技有限公司 | 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途 |
| CN116888125B (zh) * | 2021-04-07 | 2024-04-12 | 上海齐鲁制药研究中心有限公司 | Tyk2抑制剂及其用途 |
| JP7740849B2 (ja) * | 2021-05-04 | 2025-09-17 | シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド | 含窒素複素環ピリジン化合物 |
| US20240317718A1 (en) * | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| CA3223641A1 (en) * | 2021-06-22 | 2022-12-29 | Wenyuan Qian | Sulfoximine compound and use thereof |
| CN117794911A (zh) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| WO2023027948A1 (en) * | 2021-08-21 | 2023-03-02 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| WO2023064223A1 (en) | 2021-10-11 | 2023-04-20 | Gossamer Bio Services, Inc. | Tri-substituted pyridines |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| TW202339749A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商凌科藥業有限公司 | Ｔｙｋ２抑制劑及其組合物和方法 |
| EP4206196A1 (en) | 2021-12-29 | 2023-07-05 | Almirall S.A. | Pyrimidine substituted derivatives as tyk2 inhibitors |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| WO2024020221A1 (en) * | 2022-07-21 | 2024-01-25 | Arvinas Operations, Inc. | Modulators of tyk2 proteolysis and associated methods of use |
| AU2023412260A1 (en) * | 2022-12-22 | 2025-05-29 | Usynova Pharmaceuticals Ltd. | Salt form and crystal form of pyridine multi-substituted compound and preparation method therefor |
| CN120607493B (zh) * | 2025-06-04 | 2026-04-24 | 江西科技师范大学 | 一种含嘧啶结构的酰胺类化合物及其在制备tyk2 jh2激酶抑制剂中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| KR20140108594A (ko) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도 |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| MA48602A (fr) | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
-
2019
- 2019-03-20 JP JP2020550632A patent/JP7485609B2/ja active Active
- 2019-03-20 ES ES19715330T patent/ES2944733T3/es active Active
- 2019-03-20 WO PCT/US2019/023111 patent/WO2019183186A1/en not_active Ceased
- 2019-03-20 US US16/982,937 patent/US11597721B2/en active Active
- 2019-03-20 KR KR1020207029906A patent/KR102741437B1/ko active Active
- 2019-03-20 EP EP19715330.7A patent/EP3768667B1/en active Active
- 2019-03-20 CN CN201980020946.5A patent/CN111936486B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2944733T3 (es) | 2023-06-23 |
| JP2021518389A (ja) | 2021-08-02 |
| US20210032220A1 (en) | 2021-02-04 |
| JP7485609B2 (ja) | 2024-05-16 |
| WO2019183186A1 (en) | 2019-09-26 |
| EP3768667A1 (en) | 2021-01-27 |
| KR20200135425A (ko) | 2020-12-02 |
| US11597721B2 (en) | 2023-03-07 |
| CN111936486A (zh) | 2020-11-13 |
| EP3768667B1 (en) | 2023-04-12 |
| CN111936486B (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7485609B2 (ja) | ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 | |
| JP7490107B2 (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP6458038B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 | |
| TWI582077B (zh) | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 | |
| EP3917912B1 (en) | Amide-disubstituted pyridine or pyridazine compounds | |
| JP7097875B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 | |
| WO2021222153A1 (en) | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators | |
| JP7145850B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なヘテロ二環化合物 | |
| JP2020502268A (ja) | Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 | |
| KR102865925B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 | |
| EA046543B1 (ru) | Амидзамещенные гетероциклические соединения | |
| EA041710B1 (ru) | Сульфон-, пиридин-, алкил-, амидзамещенные гетероарильные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20201019 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220318 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20240520 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241203 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241206 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241206 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |